Menu
Search Close

News

Stimulation of killer CD4 T cells with potent anti-tumour activity

15th August 2012

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The Directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed. 

CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA. CD4 cells are vital for effective anti-tumour immunity. Scancell has identified and patented a series of modified epitopes that overcome this limitation. Scancell’s Moditope technology produces killer CD4 T cells that destroy tumours without toxicity 

Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: “Not only do these unique epitopes stimulate a CD4 killer T cell response, we have also shown in tests that cancer patients can produce an immune response to these epitopes. The Moditope epitopes can be used to develop both DNA and peptide vaccines and could become an important component of many therapeutic vaccines in the future, both under development at Scancell and other companies” 

Prof Peter Stern, Head of the Cancer Research UK, Immunology Group at the Paterson Institute for Cancer Research, commented: “This novel technology has the potential to transform the therapeutic cancer field. It is increasingly recognised that combining products and technologies will unlock the full potential of cancer vaccines. The Moditope technology offers those developing cancer vaccines, a means to optimise the potency of their immune targets”. 

David Evans, Chairman of Scancell Holdings, commented: "This highly innovative discovery opens up a new approach to the development of cancer vaccines. Whilst currently at an early stage, we are aware that the opportunities could be considerable in addition to Scancell’s existing platform technology. As a result, the Board is actively evaluating its strategic options for this new technology platform and will be consulting with key shareholders in this regard. We are excited by the potential and are resolute in our aim of creating the greatest value for shareholders. The Board will update the market in due course.” 

The Directors of the issuer accept responsibility for this announcement. 

                                                                                                 -ENDS-

For Further Information: Dr Richard Goodfellow, Joint CEO 

Professor Lindy Durrant, Joint CEO 

Scancell Holdings Plc 

Scancell Holdings Plc 

+ 44 207 653 9850 

+ 44 207 653 9850 

Graham Herring/Heather Armstrong 

Newgate Threadneedle 

+ 44 207 653 9850 

Ross Andrews / Tom Rowley 

Zeus Capital 

+ 44 161 831 1512 

Jon Belliss/Karen Kelly 

Xcap Securities Plc 

+ 44 207 101 7070 

Webcasts, Interviews and Media Coverage

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00